SLC۱۹A۱ and Thymidylate Synthase Polymorphisms Do not Predict Survival Outcome in Non-Small-Cell Lung Cancer Treated with Pemetrexed-Cisplatin Chemotherapy Regimen

Background: Lung cancer is the leading cause of cancer deaths worldwide. Pharmacogenomics plays an important role in tailoring cancer patients’ treatment. Pemetrexed is widely used in first- and second-line chemotherapy of non-small cell lung cancer (NSCLC); however, there is no available predictive biomarker for pemetrexed treatment. The present study aimed to investigate the role of polymorphisms in thymidylate synthase and SLC۱۹A۱ polymorphisms with clinical outcome in patients with advanced NSCLC treated in first-line with pemetrexed or pemetrexed plus cisplatin.Method: This cohort study included ۴۰ metastatic lung cancer patients treated with pemetrexed plus cisplatin. We utilized the tetra-primer amplification refractory mutation system-polymerase chain (ARMS-PCR) reaction for genotyping of rs۳۷۸۸۱۸۹ and rs۱۰۵۱۲۹۸. TYMS ۲۸-VNTR and rs۱۶۴۳۰ were genotyped in the patients via PCR amplification and PCR-RFLP, respectively. Fisher's exact test and Kaplan-Meier curve were used for statistical analysis.Results: We recruited ۴۰ patients in this research with a median age of ۵۸.۹ years. The median survival of all the ۴۰ patients was ۱۱.۶ months. The overall survival of the patients, as well as their gender, age, and metastatic sites were not found to be statistically associated with rs۱۰۵۱۲۹۸, rs۳۷۸۸۱۸۹, TYMS VNTR, and rs۱۶۴۳۰.Conclusion: Our study did not identify any associations between the SLC۱۹A۱ and TYMS VNTR and rs۱۶۴۳۰ and clinical outcomes in advanced NSCLC patients. However, further investigation will be conducive to finding effective clinical biomarkers for the treatment of patients with NSCLC.

کلیدواژه ها:

Non-small cell lung cancer ، Thymidylate synthase ، SLC۱۹A ، Pemetrexed ، Polymorphism